Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides

The Journal of Dermatology
Makoto SugayaKeiji Iwatsuki

Abstract

A multisite, open-label, non-randomized, single-arm phase II study was conducted to evaluate the efficacy and safety profiles of interferon-γ in Japanese patients diagnosed with stage IA-IIIA mycosis fungoides (MF). Interferon-γ was administrated i.v. to 15 patients at a dose of 2 million Japan reference units once daily over 5 days a week for the first 4 weeks, followed by subsequent intermittent injection. The primary efficacy end-point was the overall skin response during the study as assessed according to the evaluation criteria for chemotherapeutics for malignant skin carcinomas. Of the 15 patients, 11 (73.3%) achieved the objective response. Of the other four patients, three remained on treatment during study with stable disease and one showed disease progression. The median duration of stable disease was not reached but was 170 days or more (range, 29 to ≥253 days). As assessed according to the modified severity weighted assessment tool, nine patients (60.0%) achieved the objective response. The most common drug-related adverse event (AE) was influenza-like illness occurring in all patients enrolled, which did not lead to discontinuation of the study. Two serious AE were reported in two patients: aggravation of MF and ag...Continue Reading

References

Oct 15, 1994·Annals of Internal Medicine·P A BunnJ L Aeling
Jun 5, 1998·Leukemia & Lymphoma·R DummerG Burg
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E C de ConinckR T Hoppe
Feb 5, 2005·Blood·Rein WillemzeChris J L M Meijer
May 28, 2010·The Journal of Investigative Dermatology·Tomomitsu MiyagakiShinichi Sato
Jun 26, 2010·Journal of Dermatological Science·Makoto Sugaya

❮ Previous
Next ❯

Citations

Oct 4, 2015·The Journal of Dermatology·Masutaka Furue, Takafumi Kadono
Oct 5, 2015·Dermatologic Clinics·Natalie Spaccarelli, Alain H Rook
Dec 22, 2016·Expert Review of Hematology·Pooja VirmaniPierluigi Porcu
Jan 21, 2014·The Journal of Dermatology·Keiji IwatsukiUNKNOWN Japanese Skin Cancer Society - Lymphoma Study Group
Jun 12, 2018·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Kevin C ConlonThomas A Waldmann
Apr 20, 2018·American Journal of Respiratory and Critical Care Medicine·Zheng DengKefang Lai
Oct 19, 2019·The Journal of Dermatology·Hiroaki Kamijo, Makoto Sugaya
Jul 17, 2018·Frontiers in Immunology·Mengjia TangXijie Yu
Apr 18, 2019·American Journal of Clinical Dermatology·Robert DuffyJoya Sahu
Mar 25, 2018·Current Oncology Reports·Louise PhotiouH Miles Prince
Jun 20, 2018·Frontiers in Oncology·Kazuyasu Fujii
Oct 28, 2020·International Journal of Dermatology·Marina P TorrealbaMaria N Sato
Nov 28, 2020·The Journal of Dermatology·Mikio OhtsukaMakoto Sugaya
Dec 23, 2020·Journal of the American Academy of Dermatology·David M WeinerAlain H Rook
Feb 6, 2021·Pharmaceutics·Taku FujimuraSetsuya Aiba
Jan 9, 2021·Current Treatment Options in Oncology·Hiroaki Kamijo, Tomomitsu Miyagaki
Sep 28, 2021·Current Treatment Options in Oncology·Caitlin M BrumfielAaron R Mangold

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.